Grant-Huerta Yanina's Form 4 filing
Atara Biotherapeutics, Inc.ATRA · filed Mar 4, 2026
- Accession no.
- 0000905148-26-001144
- Filed
- Mar 4, 2026
- Trade date
- Mar 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $10.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grant-Huerta YaninaCIK 0002064348 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Common Stock | SSaleDisposed | −24 | $5.08F2 | −$121.92 | 33,830 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −1,603 | $5.08F2 | −$8,143.24 | 32,227 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −377 | $5.08F2 | −$1,915.16 | 31,850 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −100 | $5.08F2 | −$508 | 31,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Referenced by the price of 4 transactions in Table I.